{"Clinical Trial ID": "NCT03366428", "Intervention": ["INTERVENTION 1:", "DS-8201a", "Participants who received 6.4 mg/kg of DS-8201a intravenous infusion (IV) once every 3 weeks on day 1 of each 21-day cycle."], "Eligibility": ["Incorporation criteria:", "A non-resectable or metastatic breast cancer documented pathologically with the expression HER2 (immunohistochemistry [IHC] 3+, IHC 2+, IHC 1+ and/or hybridization in situ [ISH] +) which is refractory or intolerable with standard treatment, or for which no standard treatment is available", "At left ventricular ejection fraction (VEF) 50%", "At a score of 0 or 1 from the Eastern Cooperative Oncology Group (ECOG PS)", "- Exclusion criteria:", "Has a medical history of myocardial infarction within 6 months of registration", "Has a medical history of ventricular arrhythmias, other than rare premature ventricular contractions", "A cardiovascular disease that is uncontrolled or severe"], "Results": ["Performance measures:", "- QTcF changes after treatment with DS-8201a in participants with metastatic and/or non-resectable breast cancer expressed in HER2", "The number of participants whose electrocardiogram has undergone significant changes meeting predefined criteria is indicated.", "Time limit: Screening (within 7 days prior to registration) up to cycle 3 Day 15 (each cycle is 21 days)", "Results 1:", "Title of arm/group: DS-8201a", "Description of the arm/group: Participants who received 6.4 mg/kg of DS-8201a intravenous infusion (IV) once every 3 weeks on day 1 of each 21-day cycle.", "Total number of participants analysed: 49", "Type of measure: Number of participants", "Unit of measure: Participants Maximum change from QTcF reference value: > 30 ms: 3 6.1 per cent", "Maximum change from reference value in QTcF: > 60 ms: 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 9/51 (17.65%)", "Nausea 2/51 (3.92%)", "Cellulite 1/51 (1.96%)", "Lung infection 1/51 (1.96%)", "- Fracture of the femur 1/51 (1.96%)", "A post-procedure complication 1/51 (1.96%)", "Fracture 1/51 (1.96%)", "- Interstitial pulmonary disorders 1/51 (1.96%)", "Pneumonia 1/51 (1.96%)"]}